CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sunovion Pharmaceuticals Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sunovion Pharmaceuticals Inc.
84 Waterford Drive
Phone: (508) 481-6700p:508 481-6700 Marlborough, MA  01752  United States Ticker: SEPR SEPR
This company ceased filing statements with the SEC on 10/20/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.) is a research-based pharmaceutical company engaged in the discovery, development and commercialization of differentiated products that are prescribed principally by primary care physicians and certain specialists. The Company is concentrating its product development efforts in two therapeutic areas: respiratory diseases and central nervous system (CNS), disorders. As of December 31, 2008, the Company’s marketed products in the United States include, LUNESTA (eszopiclone), a non-benzodiazepine sedative hypnotic, for the treatment of insomnia in adults; XOPENEX (levalbuterol HCl) Inhalation Solution, a short-acting bronchodilator, for the treatment or prevention of bronchospasm in patients; XOPENEX HFA Inhalation Aerosol, a hydrofluoroalkane, metered-dose inhaler, for the treatment or prevention of bronchospasm in adults, adolescents and children, and BROVANA Inhalation Solution. In October 2009, Dainippon Sumitomo Pharma Co., Ltd. acquired Sepracor Inc.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200912/31/2008YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Timothy J.Barberich 61 5/14/2008 1/1/1984
President, Chief Executive Officer, Director AdrianAdams 58 5/14/2007 3/1/2007
Chief Financial Officer, Executive Vice President Robert F.Scumaci 49 5/20/2008 3/1/1995
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Cynapsus Therapeutics Inc.
Elevation Pharmaceuticals, Inc.
Oryx Pharmaceuticals Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 2,400 (As of 12/31/2008)
Outstanding Shares: 110,988,138 (As of 7/31/2009)
Shareholders: 352
Stock Exchange: NASD
Federal Tax Id: 222536587
Fax Number: (508) 357-7499
Email Address: jbarnes@sepracor.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023